BeiGene's BTK in­hibitor fails to beat mar­ket leader Im­bru­vi­ca in key head-to-head study

BeiGene’s quest to de­vel­op a su­pe­ri­or BTK in­hibitor hit a ma­jor road­block on Mon­day as the com­pa­ny con­ced­ed that the drug failed a keen­ly an­tic­i­pat­ed head-to-head tri­al test­ing its re­cent­ly ap­proved drug, Brukin­sa, against the mar­ket-lead­ing Im­bru­vi­ca.

The re­sults amount to a se­ri­ous set­back for Chi­na’s BeiGene that is hop­ing to po­si­tion Brukin­sa, known chem­i­cal­ly as zanubru­ti­nib, as the best-in-class ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER